AA
TGTX icon

ALPS Advisors’s TG Therapeutics TGTX Stock Holding History

ALPS Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,150
Closed -$426K – 1117
2024
Q4 		$426K Sell
14,150
-200
-1% -$5.74K ﹤0.01% 663
2024
Q3 		$336K Buy
+14,350
New +$313K ﹤0.01% 906
2021
Q4 		– Sell
-175,064
Closed -$5.83M – 974
2021
Q3 		$5.83M Sell
175,064
-11,556
-6% -$358K 0.06% 169
2021
Q2 		$7.24M Buy
+186,620
New +$7.33M 0.06% 158

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ALPS Advisors's TGTX Position: Q1 2025 in Review

ALPS Advisors sold out of TG Therapeutics (TGTX) in Q1 2025, closing a stake of 14,150 shares — an estimated $426K sold.

ALPS Advisors first reported a position in TGTX in Q2 2021 and held it in 4 quarters. The position peaked at $7.24M in Q2 2021. 376 funds tracked by Wall St. Rank hold TGTX as of Q1 2025.

  • ALPS Advisors reported no remaining TG Therapeutics position as of Q1 2025 after selling out during the quarter.
  • ALPS Advisors sold 14,150 TG Therapeutics shares in Q1 2025, an estimated $426K.
  • ALPS Advisors first reported a position in TG Therapeutics in Q2 2021 and held it in 4 quarters.
  • ALPS Advisors's TG Therapeutics position peaked at $7.24M in Q2 2021.
  • 376 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2025.

Based on ALPS Advisors's 13F filing for Q1 2025, filed 30 Apr 2025.